This month's mag takes the relentless tittle-tattle from 'influencers' about GLP-1 before scrutinizing, deconstructing and ...
IMAAVY has become the first FDA‑approved therapy for warm autoimmune haemolytic anaemia, offering a targeted approach ...
Nxera Pharma has announced that its partner Neurocrine Biosciences has received FDA IND acceptance for a phase 2 study of NBI‑1117567 for Alzheimer’s cognition. Nxera will rec ...
GSK has announced that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli ...
A July 2026 Leerink Partners report named Carterra a core enabling technology in the growing Lab‑in‑the‑Loop market. The ...
Erasca has been granted Fast Track Designation by the FDA for ERAS‑0015, an oral pan‑RAS molecular glue being developed for ...
Avulux has received De Novo marketing authorisation from the FDA, establishing the first recognised device classification for ...
Lundbeck has secured orphan designation from the European Commission for asedebart, its investigational anti‑ACTH monoclonal ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for the rapid ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results